Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?Konstantinidou, M., Zarganes-Tzitzikas, T., Magiera-Mularz, K., Holak, T. A. & Dömling, A., 23-Apr-2018, In : Angewandte Chemie (International ed. in English). 57, 18, p. 4840-4848 9 p.
Research output: Contribution to journal › Review article › Academic › peer-review
The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.
|Number of pages||9|
|Journal||Angewandte Chemie (International ed. in English)|
|Publication status||Published - 23-Apr-2018|
- antitumor agents, PD-1, PD-L1, protein structures, protein-protein interactions, cancer immunotherapy, crystal structure, human, protein protein interaction, protein structure, review, antineoplastic agent, endogenous compound, monoclonal antibody, programmed death 1 ligand 1, programmed death 1 receptor, PROGRAMMED DEATH-1, STRUCTURAL BASIS, CANCER-IMMUNOTHERAPY, CRYSTAL-STRUCTURE, HUMAN PD-1, CELL, INHIBITORS, BLOCKADE, LIGANDS, COMPLEX